kristoff@GENBANK.BIO.NET (Dave Kristofferson) (06/28/90)
NIH GUIDE - Vol. 19, No. 23, June 22, 1990
NOTICES
INVENTIONS: IMPORTANT NOTICE FOR RESEARCH GRANTEES AND RESEARCH
CONTRACTORS (Minor Revisions, June 1990) .................(84/312)........... 1
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
Index: NATIONAL INSTITUTES OF HEALTH
ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION
UPDATE ON THE NIH POLICY REGARDING PROGRAM PROJECT, AND OTHER COMPLEX
MULTIFACETED, UNSOLICITED GRANT APPLICATIONS .............(321/470).......... 4
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
NOTICES OF AVAILABILITY (RFPs AND RFAs)
VISIBLE HUMAN PROJECT (RFP) ..............................(484/543).......... 6
National Library of Medicine
Index: NATIONAL LIBRARY OF MEDICINE
ONGOING PROGRAM ANNOUNCEMENTS
ADDENDUM: RESEARCH GRANTS ON NARCOLEPSY (PA-90-03) ......(564/613).......... 7
National Institute of Neurological Disorders and Stroke
National Institute of Mental Health
Index: NEUROLOGICAL DISORDERS, STROKE, MENTAL HEALTH
MULTIDISCIPLINARY RESEARCH ON SOLID TUMORS (PA-90-17) ....(616/779).......... 7
National Cancer Institute
Index: CANCER
NOTICES
INVENTIONS: IMPORTANT NOTICE FOR RESEARCH GRANTEES AND RESEARCH CONTRACTORS
(Minor Revisions, June 1990)
P.T. 34; K.W. 1014006, 1016004
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
The following comments provide a brief review of current regulations affecting
inventions made with support from the National Institutes of Health (NIH) and
the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) research
grants or related awards (G, H, K, M, P, R, S, and U awards); research and
development contracts (N01 awards); and grants and contracts (N43, N44, R43,
and R44 awards) made under the Small Business Innovation Research Program.
Inventions made solely by trainees or fellows (assisted only by a T or F
award) are not subject to these guidelines.
Congress has long encouraged the use of the patent system by universities,
non-profit organizations, and small business firms. The principal concern is
to protect the public interest in inventions developed with the aid of Federal
funds, while giving due recognition to the legitimate interests of those who
have contributed to the invention. The key provisions of patent law as they
apply to inventions made with NIH and ADAMHA support are contained in several
references cited at the end of this notice under "Citations." The following
guidelines, based on those sources, describe procedures for the reporting and
subsequent disposition of such inventions.
DISCLOSURE: Federal law requires that any invention arising from
experimental, developmental, or research activities assisted by public funds
from Government grants and contracts be promptly and fully reported
(disclosed) by the inventor to his or her employer, i.e., the contractor or
grantee organization (non-profit or for-profit, public or private). In turn,
the organization must fully disclose the invention to the NIH or ADAMHA at the
address shown immediately below. This disclosure must be submitted within a
reasonable time (60 days) of the inventor's initial report to the organization
and it shall be sufficiently complete in technical detail to convey a clear
understanding of the invention. The disclosure will also identify the
inventor, the grant or contract under which the invention was made, and any
publication or manuscript submitted for publication that describes the
invention. NOTE: Many organizations disclose inventions by providing a
single copy of any report form the inventor submits for the organization's
internal use. However, reporting an invention to the NIH or ADAMHA by merely
submitting its title or summary description is NOT an acceptable disclosure.
Since these disclosure reports contain proprietary information they are not
released to the public without the organization's specific permission.
MAILING ADDRESS: The following office is the designated receipt point for any
of the documents described in this Notice, as well as for any
invention-related inquiries:
Extramural Inventions Office
National Institutes of Health
ATTN: Dr. Howard Jenerick
Building 31, Room 5B-41
Bethesda, MD 20892
Telephone: (301) 402-0850
INVENTION RIGHTS: Most Government grant and contract awards for the
performance of experimental, developmental, or research work incorporate
standard patent rights clauses which state that, subject to certain
limitations, the ownership of rights to any invention is usually left with the
contractor or grantee organization. However, the organization must elect in
writing whether or not to retain title to the invention during the next one or
two years (see below) after the required disclosure to the Extramural
Inventions Office. Any organization electing to retain the title agrees to
file an initial patent application within a reasonable period of time, i.e.,
one year or prior to any statutory bar date. If the organization elects not
to take title and file for a patent, it must so inform the NIH or ADAMHA which
then have the right to take title. (The title does not flow to the inventor
by default.) Agency staff will promptly evaluate the invention and will file a
patent application for the Government if this seems in the public interest and
it is practical to do so. If the Government obtains a patent, the
organization may retain a nonexclusive, royalty-free license and the inventor
may receive royalty payments according to a standard formula. If the agency
elects not to exercise the Government's rights in the invention, the
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 1
organization may request these rights be granted back to the inventor who may
then file for a patent.
PATENT APPLICATION and ACKNOWLEDGEMENT: At the time the organization or the
inventor submits the formal application to the U.S. Patent and Trademark
Office, a copy should also be sent to the Extramural Inventions Office along
with the obligatory license (see below). The patent application must include
the following statement:
"This invention was made with Government support under (identify the
grant/contract) awarded by the (cite the awarding agency, e.g., National
Institutes of Health or Alcohol, Drug Abuse, and Mental Health
Administration). The Government has certain rights in the invention."
TIMELINESS for ELECTION OF RIGHTS and FILING of PATENT APPLICATIONS: Timing
is critical in patent law because of statutory deadlines which must be met to
avoid loss of valuable patent rights. The laws distinguish between inventions
that are "disclosed" by confidential reporting to the Government and
inventions that are "disclosed" to the public through speeches or
publications. NOTE: Abstracts and posters presented at scientific meetings
are considered as publications, and if the published abstracts for society
meetings are mailed out early, the POST MARK DATE is considered the
publication date.
If the invention has NOT been disclosed to the public, i.e., it has only been
reported to the Government on a confidential basis, there is the two-year open
period for taking title and then another year for filing a patent application.
Timing for United States Patent Applications after Public Disclosure: Under
U.S. patent law a valid patent application may be filed only within a one-year
open period after the publication date of a printed article that discloses the
invention.
Timing for Foreign Patent Applications after Public Disclosure: Other
countries usually do not allow a one-year open period after publication,
unless a U.S. patent application has been filed prior to the publication date.
Note: Despite a possible lack of interest in foreign filing, organizations
should be aware that inattention to the proper timing between publication and
filing a U.S. patent application will cause the loss of the Government's
rights to foreign patents.
NOTE: If no application is filed during these open periods, the invention is
considered to have been dedicated to the public and can no longer be patented.
Since the Government and the inventor have certain rights to the invention as
outlined above, the limited open periods for seeking patent protection makes
it important for the organization to proceed promptly in its evaluation of the
invention and inform the Extramural Inventions Office of its decision in
timely fashion.
LICENSE: Every patent applicant (individual or institutional) is required to
provide the Government with a nonexclusive, irrevocable, paid-up license in
the invention. (A sample license form is provided at the end of this Notice.)
A single copy of this license should be sent to the Extramural Inventions
Office at the time the patent application is filed.
PATENT: The successful applicant will furnish a copy of the issued patent to
the Extramural Inventions Office.
PREFERENCE FOR UNITED STATES INDUSTRY: The patent holder or its assignee will
not license or grant any person the exclusive right to use or sell the
invention in the United States unless the products are manufactured
substantially in the United States.
INVENTION UTILIZATION REPORTS: Periodic utilization reports for each
invention must be filed with the Extramural Inventions Office. Such reports
shall be submitted every two years and shall include information regarding the
status of development, date of first sale or use, and gross royalties received
by the organization. These utilization reports are not releasable to persons
outside the Government without permission of the grantee or contractor, or
within the Government except on a need-to-know basis.
SPECIAL NOTE: Chemical compounds having potential medicinal or other
utilities are often synthesized or identified during research financed by
Federal funds. Such a compound is not patentable until a use can be
described. Although the compound need not be tested, the patent application
must "teach" the reader how to use the substance. It is NIH and ADAMHA policy
that such compounds should be adequately screened so that all possible uses
may be ascertained and any promising compounds be developed for widest
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 2
possible use. The screening services of the National Cancer Institute and the
Walter Reed Army Institute of Research should be utilized for this purpose,
whenever appropriate.
LEGAL CONTACT: It is important that institutions rely primarily on their own
legal counsel for advice and interpretation of relevant Governmental laws and
regulations. However, if a technical question arises that requires an answer
from a Government patent attorney please contact:
Patent Branch
DHHS Office of the general Counsel
Public Health Division
National Institutes of Health
Building 31, Room 2B-62
Bethesda, MD 20892
Telephone: (301) 496-7056
INVENTION REPORTS in GRANT APPLICATIONS and FINAL REPORTS: Please note that
inventions arising from NIH and ADAMHA supported projects must be reported to
the awarding component in competing and non-competing applications for
continuation awards. To insure confidentiality, inventions reported through
this channel should be described by title or summary paragraph only. It may
be wise to discuss these descriptions with the organization's patent counsel
before submission.
At the expiration or termination of each project, the Final Invention
Statement and Certification (Form HHS 568) is sent to the Grants Management
Officer of the awarding component. In the case of terminated contracts any
inventions are identified in the contract close-out letter. (NOTE: Grantees
are reminded that the Statement is required within 90 days following the
expiration or termination of support for the project.) Because of brevity,
these latter reports do not meet the requirements for full disclosure.
CITATIONS: Important changes in public laws in recent years have led to
substantial revisions of the Agency regulations affecting inventions made with
Federal support. The requirements of Public Laws 96-517 and 98-620 are
embodied in Title 35 United States Code (USC) Sections 200-212, and have been
implemented in the regulations published in Title 37 Code of Federal
Regulations (CFR) Part 401. (The corresponding Department of Health and Human
Services regulations, 45 CFR Part 6 and 8, are currently under revision.) The
standard patent rights clauses which are incorporated into all NIH and ADAMHA
grants and research contracts appear in 37 CFR Section 401.14.
SAMPLE License form for use by Institutional Official or individual inventor:
LICENSE TO THE UNITED STATES GOVERNMENT
This instrument confers to the United States Government, as represented by the
Department of Health and Human Services, a nonexclusive, nontransferable,
irrevocable, paid-up license to practice or have practiced on its behalf
throughout the world the following subject invention. This license will
extend to all divisions or continuations of the patent application and all
patents or reissues which may be granted thereon:
Invention Title :
Inventor(s) :
Patent Application
Serial No. :
Filing Date :
Title :
Country, if other than
United States :
This subject invention was conceived or first actually reduced to practice in
performance of a government-funded project, (National Institutes of Health or
Alcohol, Drug Abuse, and Mental Health Administration grant/contract) No.
_______________________________. Principal rights to this subject invention
have been left with the
Licensor:_________________________________________________________, subject to
the provisions of 37 CFR 401 and 45 CFR 8.
Signed:___________________________________Date:__________________
Typed Name : Title :
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 3
UPDATE ON THE NIH POLICY REGARDING PROGRAM PROJECT, AND OTHER COMPLEX
MULTIFACETED, UNSOLICITED GRANT APPLICATIONS
P.T. 34; K.W. 0710030, 1014006
National Institutes of Health
The Institutes, Centers, and Divisions (ICDs) of the National Institutes of
Health (NIH) accept a variety of large unsolicited grant applications, such as
those for program projects and other large, complex coordinated research
grants. However, guidelines and policies governing preparation, review, and
funding of these applications are not uniform across the NIH and may differ
because of a variety of factors such as legislative mandates, fiscal
constraints and programmatic management.
In order to serve the extramural community better, the National Institutes of
Health advise that prior to submission of any application for an unsolicited,
multifaceted grant, applicants communicate with appropriate ICD staff. This
action will allow the applicant to be apprised of the guidelines and policies
that govern the preparation, review and funding of such applications for a
particular ICD. Of special concern is the fact that the different ICDs have
different dollar limits for such multifaceted applications, and applications
that exceed these limits will be returned without review.
The assignment of an application to a potential funding source within the NIH
is based on scientific guidelines developed for each ICD in conjunction with
the Division of Research Grants (DRG) and is the responsibility of the DRG,
not of the individual ICDs. Thus, when the potential applicant discusses
plans for a complex program grant application with the initial ICD contact,
he/she is strongly advised to inquire whether other ICDs may also have
relevant scientific interests so that additional staff contacts can be made if
appropriate.
The following individuals may be contacted for specific questions related to
such applications:
National Institute on Aging
9000 Rockville Pike
Bldg. 31, Room 5C06
Bethesda, MD 20892
Att.: Dr. Miriam Kelty
Telephone: (301) 496-9322
National Institute of Allergy and Infectious Diseases
5333 Westbard Avenue
Westwood Bldg., Room 703
Bethesda, MD 20892
Att.: Dr. John Diggs
Telephone: (301) 496-7291
National Institute of Arthritis and Musculoskeletal and Skin Diseases
9000 Rockville Pike
Bldg. 31, Room 4C32
Bethesda, MD 20892
Att.: Dr. Michael Lockshin
Telephone: (301) 496-0802
National Cancer Institute
9000 Rockville Pike
Bldg. 31, Room 10A03
Bethesda, MD 20892
Att.: Ms. Barbara Bynum
Telephone: (301) 496-5147
National Institute of Child Health and Human Development
9000 Rockville Pike
Bldg. 31, Room 2A03
Bethesda, MD 20892
Att.: Ms. Hildegard Topper
Telephone: (301) 496-0104
National Institute of Deafness and Other Communication Disorders
7550 Wisconsin Avenue
Federal Bldg., Room 1C11
Bethesda, MD 20892
Att.: Dr. Ralph Naunton
Telephone: (301) 496-1804
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 4
National Institute of Dental Research
5333 Westbard Avenue
Westwood Bldg., Room 503
Bethesda, MD 20892
Att.: Dr. Lois Cohen
Telephone: (301) 496-7723
National Institute of Diabetes and Digestive and Kidney Diseases
5333 Westbard Avenue
Westwood Bldg., Room 657
Bethesda, MD 20892
Att.: Dr. Walter Stolz
Telephone: (301) 496-7277
National Eye Institute
9000 Rockville Pike
Bldg. 31, Room 6A08
Bethesda, MD 20892
Att.: Dr. Ralph J. Helmsen
Telephone: (301) 496-5884
National Institute of Environmental Health Sciences
P.O. Box l2233
Bldg. 3, Room 301
Research Triangle Park, NC
Att.: Dr. Anne Sassaman
Telephone: (919) 541-7723
FTS 8-629-7723
National Institute of General Medical Sciences
5333 Westbard Avenue
Westwood Bldg., Room 953
Bethesda, MD 20892
Att.: Dr. W. Sue Shafer
Telephone: (301) 496-7061
National Heart, Lung and Blood Institute
5333 Westbard Avenue
Westwood Bldg., Room 7A17
Bethesda, MD 20892
Att.: Dr. Ronald Geller
Telephone: (301) 496-7416
National Institute of Neurological Disorders and Stroke
7550 Wisconsin Avenue
Federal Bldg., Room 1016
Bethesda, MD 20892
Att.: Dr. John Dalton
Telephone: (301) 496-9248
National Center for Human Genome Research
9000 Rockville Pike
Bldg. 1, Room 203
Bethesda, MD 20892
Att.: Dr. Mark Guyer
Telephone: (301) 496-0844
National Center for Nursing Research
9000 Rockville Pike
Bldg. 31, Room 5B09
Bethesda, MD 20892
Att.: Dr. Janet Heinrich
Telephone: (301) 496-0523
National Center for Research Resources
9000 Rockville Pike
Bldg. 3l, Room lB63
Bethesda, MD 20892
Att: Dr. Judith Vaitukaitis
Telephone: (30l) 496-6023
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 5
NOTICES OF AVAILABILITY (RFPs AND RFAs)
VISIBLE HUMAN PROJECT
RFP AVAILABLE: NLM-90-114/SLC
P.T. 34; K.W. 1004004, 1004005, 0705000, 0706030
National Library of Medicine
The National Library of Medicine (NLM) is undertaking a project to build a
digital image library of volumetric data representing a complete normal adult
human male and female. This "Visible Human Project" will include digital
images derived from photographic images from cryosectioning, computerized
tomography, and magnetic resonance imaging of cadavers. This project is
viewed as a cornerstone for a future set of related image libraries and a test
platform for developing methods and standards.
Technologies underlying computer-based representation and display of complex
three-dimensional biological structure are sufficiently mature that the NLM
can proceed with building prototype digital image libraries. The NLM's Long
Range Planning effort of 1985-86 foresaw a coming era where the NLM's
bibliographic and factual database services would be complemented by libraries
of digital images, distributed over high-speed computer networks and by
high-capacity physical media. The NLM Planning Panel on Electronic Imaging
was convened to recommend when and how the NLM might proceed in the
development of such digital image libraries. Much of our understanding of
complicated processes of health and disease lies in images, pictures of body
systems, organs, and molecules which cannot effectively be described in words.
This project will be implemented in three phases:
Phase 1 Acquisition of cadavers, CT and MRI data sets, and selection of a
"typical" male and female cadaver for Stages 2 and 3
Phase 2 Acquisition of anatomy data set from either male or female cadaver
Phase 3 Acquisition of anatomy data set from remaining female or male cadaver
The major technical risks associated with this project will be the selection
of the two cadavers which will prove to be appropriate for use in Phase 2 and
Phase 3; and the techniques of tissue sectioning and image capture sufficient
to obtain the required results. The Ad Hoc Technical Evaluation Committee
will provide oversight at the transition points between phases 1 and 2 and
between phases 2 and 3.
The contractor will be evaluated by the Ad Hoc Technical Evaluation Committee
after the completion of Phase 1. Such evaluation may be on the basis of the
contractor's Phase 1 report, by presentation to the committee or by site visit
to the contractor's site by committee members.
RFP NLM-90-114/SLC will be available in late June 1990, and proposals will be
due 30 days thereafter. Copies of the Request for Proposals may be obtained
by written request only to:
National Library of Medicine
Office of Acquisitions Management
8600 Rockville Pike
Building 38A, Room B1N17
Bethesda, MD 20894
Attention: Sharon Cummings
Telephone: (301) 496-6546
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 6
ONGOING PROGRAM ANNOUNCEMENTS
ADDENDUM: RESEARCH GRANTS ON NARCOLEPSY
PA: PA-90-03
P.T. 34; K.W. 0715138, 0715187, 0765035, 1002058, 0745020, 0745070
National Institute of Neurological Disorders and Stroke
National Institute of Mental Health
The program announcement was originally published in the NIH Guide, Volume 19,
No. 15, April 13, 1990. The following changes have been made to reflect the
addition of The National Institute of Mental Health (NIMH) as a co-sponsor on
this program announcement that originally was issued by the National Institute
of Neurological Disorders and Stroke (NINDS).
APPLICATION AND REVIEW PROCEDURES
Applications should be prepared on Form PHS-398 (Revised 10/88) according to
instructions contained in the application kit. Application kits are available
from most institutional business offices or may be obtained from the Division
of Research Grants. Check "Yes" in Item 2 on the face sheet of the
application and type "NINDS-NIMH grant related to Narcolepsy, PA-90-03," in
the space provided.
Applications must be responsive to the Program Announcement and the goals of
the NINDS or NIMH. Primary assignment of the grant to the sponsoring
institutes will be according to existing referral guidelines of the Division
of the Research Grants. Applications will be judged on scientific merit and
program relevance in accordance with NIH or ADAMHA policy and procedures
involving peer review. An initial review will be by an appropriate study
section. A second level of review will be by an appropriate National Advisory
Council.
For further information, applicants may contact:
Charlotte B. McCutchen, M.D.
NIH, NINDS, DCDND, EB
Federal Building, Room 114
7550 Wisconsin Avenue
Bethesda, MD 20892
Telephone: (301) 496-1917
or
Susan Blumenthal, M.D., M.P.A.
Chief, Behavioral Medicine Program
NIMH
5600 Fishers Lane, Room 11-C-06
Rockville, MD 20857
Telephone: (301) 443-4337
MULTIDISCIPLINARY RESEARCH ON SOLID TUMORS
PA: PA-90-17
P.T. 34; K.W. 0715035, 0785140, 0710030
National Cancer Institute
Application Receipt Date: February 1, June 1, October 1
The National Cancer Institute (NCI) through the Organ Systems Coordinating
Branch seeks grant applications to conduct multidisciplinary research on human
solid tumors. This program announcement encompasses a full range of studies
from basic through clinical, including technology research. Applications may
focus on one or several solid tumors. The intent of the announcement is to
encourage research on human solid tumors that contribute substantially to
cancer incidence, morbidity and mortality. The NCI is especially interested
in novel ideas and approaches to solid tumor.
I. BACKGROUND
In past years, significant progress has been reported for leukemia and
lymphoma research, but advances in solid tumor research have not been
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 7
commensurate. This disparity has been due partly to the lack of suitable
models and particularly to the lack of available human tissues. The
establishment of the Cooperative Human Tissue Network, supported through the
NCI Division of Cancer Biology, Diagnosis, and Centers, now makes human
tissues more readily available for research purposes. Thus, an increased
emphasis on human solid tumor research becomes feasible. The NCI now seeks to
stimulate novel research in the solid tumors, particularly those tumors that
account for significant cancer incidence, morbidity and mortality, e.g., lung,
colon-rectum, breast, upper aerodigestive, prostate, bladder, pancreas,
melanoma, stomach, kidney, ovary, brain. A major portion of NCI support for
research on these tumors has been in applied research, e.g., clinical trials;
basic research has received lesser attention.
In the past, NCI has supported solid tumor research through clinical
cooperative trials which have addressed a variety of solid tumors, as well as
through the Organ Systems Program (OSP) which sought to stimulate
multidisciplinary research in selected solid tumor sites (i.e., bladder,
breast, central nervous system, large bowel, pancreas, prostate, and upper
aerodigestive tract). A recent reorganization of the OSP has broadened its
responsibility to include research encompassing all solid tumors, with
emphasis on those that contribute substantially to cancer incidence, mortality
and morbidity and/or have particular significance to minorities and the aged.
II. RESEARCH GOALS AND SCOPE
This announcement seeks to encourage multidisciplinary research on human solid
tumors. Research grant applications utilizing the traditional grant
mechanisms, including the RO1 investigator initiated or the PO1 program
project grant, are encouraged. Small P01 program project applications with
three to four subprojects, addressing one or more tumor sites, would be
particularly relevant. A P01 application could be multi-institutional,
thereby providing multidisciplinary linkages not otherwise available. A full
range of research activities including basic, clinical and technology
development is within the scope of this announcement.
Examples of research areas include but are not limited to those being explored
under the previous organization of the OSP, which utilized standing working
groups of expert scientists to identify multidisciplinary research
opportunities. For example, the Bladder Cancer Working Group concluded a
workshop on "The Biology of Bladder Cancer and the Potential Implications" in
which opportunities were identified relating to stromal epithelial
interactions and oncogene activation, new potential markers in tumorigenesis,
tumor growth influence on immunobiology, development of laboratory techniques
for predicting chemotherapy and radiation responses, and opportunities for
prevention trials. The Breast Cancer Working Group has addressed interactions
between hormonal and cytotoxic adjuvant therapies and the effects of
tamoxifen, estrogens, and progestins on high-risk breast lesions. The CNS
Oncology Working Group was developing ideas for research on targets and
mechanisms of CNS radiation damage in order to understand molecular lesions
responsible for radiation injury specific to cellular elements and vasculature
of the central nervous system. The Large Bowel Cancer Working Group was
developing ideas focused on the transformation and progression of normal
colonic epithelium to adenocarcinoma, as well as protocols for conservative
treatment of rectal cancer thereby avoiding permanent colostomy. The Prostate
Cancer Working Group was addressing genetic instability and tumor
heterogeneity, the biology of latent cancer and its clinical progression, and
a re-examination of prostate epidemiology. The Upper Aerodigestive Cancer
Working Group convened a workshop on chemoprevention of upper aerodigestive
tract cancers and was developing concepts for related research initiatives.
In addition, ideas were being discussed relative to genetic susceptibility to
carcinogenesis in the upper aerodigestive tract, magnetic resonance imaging of
subclinical disease in the head and neck, and a possible viral etiology in the
epidemiology of upper aerodigestive cancers. For further information on any
of these working group activities, please call the Organ Systems Coordinating
Branch (see below). These examples focus on single tumor sites and are not
all inclusive. Other tumor sites and other areas are encouraged as well as
approaches which study tumors across organ sites.
The NCI is especially interested in novel ideas and approaches. Applicants
are encouraged to use multidisciplinary approaches for investigating common as
well as unique properties and behavior of solid tumors. Human tissues for
research purposes are available through the Cooperative Human Tissue Network
(for details call Dr. Roger Aamodt, 301/496-7147). Prospective applicants
could benefit by calling the Organ Systems Coordinating Branch (see below) to
establish relevant contacts within the NCI. If a program project application
is considered, preliminary contact should be made to assure adherence to
guidelines for program project applications. Grant applications submitted in
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 8
response to this announcement will be assigned to the relevant divisional
programs.
III. MECHANISM OF SUPPORT
This program will be supported through all traditional research grant
mechanisms including the R01 investigator initiated and P01 program project
grant mechanisms. Awards will be administered in accordance with Public
Health Service Policy as described in the PHS Grant Policy Statement, DHHS
Publication No. (OASH) 82-50,000 revised January 1, 1987.
IV. APPLICATION AND REVIEW PROCEDURES
Grant applications in response to this announcement will be reviewed in
accordance with the usual Public Health Service peer review (Study Section)
procedures. Review criteria include the significance and originality of
research goals and approaches; feasibility of research and adequacy of
experimental design; adequacy of available facilities and appropriateness of
the requested budget relative to the work proposed. Following Study Section
review, further evaluation will be provided by an appropriate National
Advisory Board/Council. Funding decisions will be based on the above
evaluations and on the availability of funds.
Applications should be submitted on Form PHS-398, revised 10/88, available in
the business or grants office at most academic or research institutions, or
from the Division of Research Grants, National Institutes of Health.
Applications will be accepted in accordance with the dates for receipt of new
applications on an indefinite basis:
February 1 June 1 October 1
The phrase "Multidisciplinary Research on Solid Tumors PA-90-17" should be
typed on line 2 of the face page of the application. The original and six
copies should be sent to:
Grant Applications Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**
For further information, please call:
Dr. Andrew Chiarodo
Organ Systems Coordinating Branch
Centers, Training, and Resources Program
Division of Cancer Biology, Diagnosis, and Centers
National Cancer Institute
Executiva Plaza North, Suite 316
Bethesda, MD 20892
Telephone: (301) 496-8528
This program is described in the Catalog of Federal Domestic Assistance No.
13.393, Cancer Prevention Program. Awards will be made under authorization of
the Public Health Service Act, Title Iii, Section 301(c) and Section 402
(Public Law 78-410, as amended: 42 USC 241; 42 Usc 282) and administered
under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR
Part 74. This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH. APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS. THE ADDRESS FOR THE WESTWOOD
BUILDING IS:
5333 Westbard Avenue
Bethesda, Maryland 20816
NIH GUIDE - Vol. 19, No. 23, June 22, 1990 - Page 9